Retatrutide targets GLP1 + GIP + glucagon, so some commentators have started calling it GLP3 to suggest a thirdgeneration medication. How Retatrutide Works: Triple Agonist Mechanism Retatrutide is being developed as a onceweekly injectable that activates GLP1, GIP, and glucagon receptors at the same time to influence appetite, blood sugar, and energy expenditure. GLP1 receptor activation Reduces appetite and food intake
Weight loss of just 5-10% can restore ovulatory cycles in many women with PCOS
It also has a half-life of around 165184 hours, allowing for weekly dosing 4
When fiber is fermented by your gut bacteria, it produces compounds that help stimulate GLP-1 production
Less commonly, alopecia areata, traction alopecia, diffuse unpatterned alopecia, or an inflammatory or scarring disorder may be responsible
Similarly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for the treatment of type 2 diabetes, have demonstrated promising cognitive benefits, potentially mediated through improved insulin signaling, neuronal survival, and reduced -amyloid (A) and tau burden
